Forty-eight weeks treatment with clevudine 30 mg qd versus lamivudine 100 mg qd for chronic hepatitis B infection: a double-blind randomized study

BACKGROUND/AIMS: Clevudine is a pyrimidine analogue with potent activity against hepatitis B virus (HBV) replication in vitro. In a previous pivotal phase III clinical study, 24 weeks treatment with clevudine 30 mg has been shown to profoundly suppress HBV replication and normalize serum alanine ami...

Descripción completa

Detalles Bibliográficos
Autores principales: Lau, George KK, Leung, Nancy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Association for the Study of the Liver 2010
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3304600/
https://www.ncbi.nlm.nih.gov/pubmed/20924215
http://dx.doi.org/10.3350/kjhep.2010.16.3.315

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3304600/
https://www.ncbi.nlm.nih.gov/pubmed/20924215
http://dx.doi.org/10.3350/kjhep.2010.16.3.315

Ejemplares similares